Analyst Activity – Wedbush Reiterates Outperform on Aimmune Therapeutics (NASDAQ:AIMT)

Analyst Ratings For Aimmune Therapeutics (NASDAQ:AIMT)

Story continues below

Today, Wedbush reiterated its Outperform rating on Aimmune Therapeutics (NASDAQ:AIMT) with a price target of $42.00.

There are 4 buy ratings on the stock.

The current consensus rating on Aimmune Therapeutics (NASDAQ:AIMT) is Buy (Score: 3.00) with a consensus target price of $36.25 per share, a potential 64.77% upside.

Some recent analyst ratings include

  • 7/24/2017-Wedbush Reiterated Rating of Outperform.
  • 3/22/2017-Piper Jaffray Companies Reiterated Rating of Overweight.
  • 9/26/2016-JMP Securities initiated coverage with a Outperform rating.
  • 8/19/2016-Credit Suisse Group Reiterated Rating of Buy.
  • 5/16/2016-Bank of America Corporation Reiterated Rating of Buy.

Recent Insider Trading Activity For Aimmune Therapeutics (NASDAQ:AIMT)
Aimmune Therapeutics (NASDAQ:AIMT) has insider ownership of 24.56% and institutional ownership of 69.62%.

  • On 7/21/2017 Douglas T. Sheehy, Insider, sold 7,460 with an average share price of $21.66 per share and the total transaction amounting to $161,583.60. View SEC Filing
  • On 7/17/2017 Mary M Rozenman, Insider, sold 14,940 with an average share price of $21.44 per share and the total transaction amounting to $320,313.60. View SEC Filing
  • On 7/5/2017 Mary M Rozenman, Insider, sold 45,060 with an average share price of $20.85 per share and the total transaction amounting to $939,501.00. View SEC Filing
  • On 7/3/2017 Susan E Barrowcliffe, Insider, sold 15,000 with an average share price of $20.26 per share and the total transaction amounting to $303,900.00. View SEC Filing
  • On 6/23/2017 Stephen George Dilly, Insider, sold 49,400 with an average share price of $20.21 per share and the total transaction amounting to $998,374.00. View SEC Filing
  • On 5/12/2017 Eric Bjerkholt, CFO, bought 5,000 with an average share price of $19.84 per share and the total transaction amounting to $99,200.00. View SEC Filing
  • On 5/10/2017 Stephen George Dilly, Insider, sold 600 with an average share price of $20.15 per share and the total transaction amounting to $12,090.00. View SEC Filing

Recent Trading Activity for Aimmune Therapeutics (NASDAQ:AIMT)
Shares of Aimmune Therapeutics closed the previous trading session at 22.00 up +0.24 1.10% with 143,624 shares trading hands.

An ad to help with our costs